Blood pressure drug study in septic shock halted early
NCT ID NCT06426407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study aimed to understand why some septic shock patients respond better to the drug vasopressin. Researchers planned to compare blood markers, heart ultrasound images, and tissue oxygen levels between responders and non-responders. However, the study was terminated after enrolling only 2 participants, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vasopressin
- What this could lead to
- If successful, this could help doctors identify which septic shock patients benefit most from vasopressin, potentially leading to more personalized treatment.
- What could go wrong
- The study was terminated early with only 2 participants, so results are very limited and may not be reliable or generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHOCK, SEPTIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ultrasound help doctors give the right amount of fluids in septic shock?
- New sensor could replace painful finger pricks for ICU patients
- Triple-Drug cocktail for septic shock shows promise in small trial
- Timing of steroids could save lives in sepsis
- New heart imaging study seeks clues in septic shock survival
- Fingertip test may rival blood test in sepsis care